INTRODUCTION
Metastases of solid tumours represent the most-important target for therapy in that they are the most frequent responsible for the failure of cancer therapy. Metastases are always scattered, often in more than one vital organ, and ate not erasable by conventional surgery and/or radiotherapy. On the other hand, cytotoxic cancer chemotherapy fails against solid tumour metastases in that, among all, metastases differ from the primary tumours of origin because of poor sensitivi to conventional drugs [1] [2] [3] . Drugs active against metastases are therefore strongly desired. These drugs should show the capacity of inhibitin metastasis growth (i.e. the growth of metastases already formed), besides metastass formation (i.e. the steps that bring turnout cells to form distant metastases) [4] . It is thus important to get the so-called antimetastasis agents rather than the mostly known antimetastatc drugs, provided that in human beings the most probable drug treatment is for already established metastases. In recent years, we accumulated a strong evidence for the effects of some ruthenium complexes on solid tumour metastases in mice bearing experimental tumours [5] [6] [7] . Of [7, [9] [10] [11] . More recently, NAMI-A, though undergoing a series of molecular metabolisms in aqueous solutions, was shown capable of maintaining its antimetastatic activity in a broad range of experimental conditions, thus suggesting the possibility of handling its clinical management in a rather flexible way [12] . Figure 1 . On 0 metastasis number, NAMI-A caused the reduction to about 55-60 A of untreated controls at any dose tested from 150 to 600 mg/kg/day; the submission of these results to the one-way analysis of variance showed a signi-ficant reduction at the doses of 150 and 600 mg/kg/day, indicating that the rather wide variation observed in the treated groups rediced the statistical significance at the other doses. ed differences can be considered statistically significant.
The measurement of ruthenium in the kidney of mice treated orally with NAMI-A shows that the concentration of the metal (referred as NAMI-A) increases proportionally to the daily dose used (Figure 3) . Indeed, the amount ofNAMI-A found in the kidney of these animals was markedly lower than after i.p. administration. By comparison we may report the data obtained with the dose of 35 mg&g/day given daily for 6 consecutive days. In this case, the amount of NAMI-A found in the kidney was approximately 10 to 20-f01d greater than that reported in Figure 3 , at the higher dose of 600 mg/kg/day for 11 consecutive days.
The kidneys of mice of Figure 1 were processed for flameless atomic absorption spectroscopy analysis of ruthenium content. Each value is the mean+S.E, obtained from at least three separate samples obtained from three different mice per group. The oral treatment with NAMI-A induces a marked modification of the appearance of tumour parenchyma, particularly at the external border which appears more regular at the interface with the surrounding tissue and with an increased density of connective tissue.
Apparently, mmour cells do not appear to be modified by the treatment with NAMI-A and their density is similar to that of the control samples. At a greater magnification it is possible to appreciate better the changes at the border of the primary mmour mass on Which severalinflammatory cells are distinguishable. These alteration are perfectly similar to those observed following i.p. treatment of this turnout [5] . A detailed examination of the cells of Figure 5 shows the presence of infiltrating leukocytes, particularly PMNs and lymphocytes (shown by arrows), already evidenced following the i.p. treatment in primary tumour masses of both i.m. and s.c. growing tumours [13] . The examination of gut epithelium and kidney parenchyma, of mice treated orally with NAMI-A, by histological staining and light microscopy analysis, showed no appreciable alteration of the architecture of the tissues examined ( Figure 6 ). Gut epithelium was regular and the only change consisted of an increased density of connective tissue on the basal membrane over untreated controls. Kidney tubules and glomeruli appear regular with cells well defined and no presence of cell suffering, dilation of tubules or swelling of the extracellular matrix. 
CONCLUSION
Among the most important promising ruthenium complexes appeared in the literature [15] [16] , those with sulf0xide ligands still continue to show the better pharmacological properties against solid tumour metastases.
NAMI-A proved to be active against solid tumour metastases also when given by the oral route over a 10 day period to mice with advanced MCa mammary carcinoma. Although the overall effect-is slightly less pronounced than that obtained following i.p. treatment, it must be stressed that by this route of administration the kidney concentration of the compound is markedly lower and no histological toxicity is evidenced. The lack of toxicity at the gut level and on kidneys suggest the possibility to use NAMI-A by this route also for periods longer than that usedin tfi6 present study. Provided that to keep metasases under full control by non cytotoxic drugs such as NAMI-A, they should be treated for long periods, these data suggest the feasibility of this treatment and its effectiveness.
